Skip to content

Public FDA record

Z-1947-2024: Leica HistoCore PEGASUS Tissue Processor, REF 14048858005.

Recall record Z-1947-2024 for LEICA BIOSYSTEMS NUSSLOCH GMBH. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1947-2024
Company in FDA record
LEICA BIOSYSTEMS NUSSLOCH GMBH
FDA classification date
Jun 4, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Poorly processed and/or damaged biopsy tissue specimens on the device resulting from reagent levels exceeding the maximum fill level marks on reagent bottles or in the paraffin tanks.

Source facts

Action
The recalling firm issued letters to the Canadian consignees on 4/10/2024 via email and to the U.S. consignees on 4/18/2024 via email. The letter explained the reason for recall, the impact of the issue, and advice on immediate actions to be taken. The actions were: (1) Check reagent status in reagent bottles and paraffin status in paraffin bath. In case of any signs of contamination (such as muddiness, turbidity, or liquid separation) are observed, you should stop using the instrument for tissue processing and call for service. When no cross-contamination is observed, continue with the following: (a) In order to ensure defined condition, please check reagent/paraffin level. If they are over the maximum level mark, you should pour out the excess reagent/paraffin, and empty the condensation bottle; (b) To secure further processing, reagent and wax bath levels shall be always checked in terms of not exceeding maximum fill level. As long as maximum fill level is between the minimum and maximum level, your instrument is fine, and you can continue processing. (2) Before running the protocol, inspect the reagent level in reagent bottles and paraffin level in paraffin baths. Make sure that all processing reagents and paraffin level is between the Min and Max. and regularly empty the condensation bottle (weekly). (Refer to IFU 2.2.3 Operating the instrument; 9.3 Cleaning and maintenance schedule). (3) The reagent bottle and paraffin bath should be filled between the Min and Max line as indicated in the Instructions for Use. (Reagent level: Refer to IFU 4.4 Basic instrument/hardware 4.4.1 Retorts). (4) Formalin should be dripped out from the basket before adding it into the retort to avoid large carryover volume of formalin into the reagent bottle. (5) Please check if the current carrier material has large volume of carryover. If yes, please change to an appropriate carrier material. (6) Please do not clean the Mold or metal lid in the retort during the cleaning p
Initiated
2024-04-10
Root cause
Device Design
Distribution
Worldwide - US Nationwide distribution including in the states of AK, AL, AZ, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MT, NC, NJ, NV, NY, OH, TN, TX, UT, VA, WA, and WI. There was also government distribution but no military distribution. The country of Canada.
Recall number
Z-1947-2024
Recall status
Open, Classified
CDRH record ID
207270
FDA classified
2024-06-04
Recall event number
94470

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗